1. Transmembrane domain–driven PD-1 dimers mediate T cell inhibition.
- Author
-
Philips, Elliot A., Liu, Jia, Kvalvaag, Audun, Mørch, Alexander M., Tocheva, Anna S., Ng, Charles, Liang, Hong, Ahearn, Ian M., Pan, Ruimin, Luo, Christina C., Leithner, Alexander, Qin, Zhihua, Zhou, Yong, Garcia-España, Antonio, Mor, Adam, Littman, Dan R., Dustin, Michael L., Wang, Jun, and Kong, Xiang-Peng
- Subjects
PROGRAMMED cell death 1 receptors ,T cells ,CYTOTOXIC T cells ,T cell receptors ,TRANSMEMBRANE domains ,DIMERS - Abstract
Programmed cell death-1 (PD-1) is a potent immune checkpoint receptor on T lymphocytes. Upon engagement by its ligands, PD-L1 or PD-L2, PD-1 inhibits T cell activation and can promote immune tolerance. Antagonism of PD-1 signaling has proven effective in cancer immunotherapy, and conversely, agonists of the receptor may have a role in treating autoimmune disease. Some immune receptors function as dimers, but PD-1 has been considered monomeric. Here, we show that PD-1 and its ligands form dimers as a consequence of transmembrane domain interactions and that propensity for dimerization correlates with the ability of PD-1 to inhibit immune responses, antitumor immunity, cytotoxic T cell function, and autoimmune tissue destruction. These observations contribute to our understanding of the PD-1 axis and how it can potentially be manipulated for improved treatment of cancer and autoimmune diseases. Editor's Summary: Programmed cell death-1 (PD-1) is well known as an immune checkpoint receptor on T cells that can inhibit activation upon engagement with its ligands PD-L1 or PD-L2. PD-1 has largely been considered to function as a monomer, but Philips et al. now show that PD-1 can form dimers in cis via transmembrane domain interactions. They observed that limiting PD-1 dimerization weakens T cell inhibition upon ligand engagement, which enhances antitumor and cytotoxic T cell function and promotes autoimmunity. These findings may shape ongoing efforts to more effectively block PD-1 function or, conversely, to develop PD-1 agonists. —Christiana Fogg [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF